Glimeto-PM2 Tablets

Glimeto-PM2 is a triple combination anti-diabetic therapy designed for effective control of Type 2 Diabetes Mellitus. It combines the complementary actions of Metformin SR, Glimepiride, and Pioglitazone to target multiple pathophysiological defects of diabetes, ensuring better glycemic control and improved insulin sensitivity.

Triple Action Control
Metformin SR → Reduces hepatic glucose production & improves insulin sensitivity
Glimepiride → Stimulates insulin secretion from pancreatic β-cells
Pioglitazone → Enhances peripheral insulin sensitivity
Key Benefits
Provides comprehensive glycemic control
Controls both fasting & postprandial glucose levels
Improves insulin sensitivity
Reduces risk of diabetes-related complications
Convenient once-daily or physician-directed dosing
Composition

Each bilayered tablet contains:

Metformin Hydrochloride (SR) IP – 500 mg
Glimepiride IP – 2 mg
Pioglitazone Hydrochloride IP (eq. to Pioglitazone) – 15 mg
Excipients – q.s.
Indications
Type 2 Diabetes Mellitus
Patients not controlled on dual therapy
Insulin resistance with poor glycemic control
Dosage & Administration
As directed by the physician
Swallow whole; do not crush or chew
Storage Instructions
Store below 25°C
Protect from light & moisture
Safety Information
Schedule H Prescription Drug
Not to be sold without prescription
Keep out of reach of children
Packaging
10 x 15 Tablets